Streetbeat News

Price Targets

HRTS

During Benzinga's ETFS Unlocked Event, the CIO of Tema discussed the Cardiovascular and Metabolic ETF, highlighting significant innovation in the sector that presents new investment opportunities. Additionally, the current downcycle in biotech was noted as creating attractive valuation opportunities for investors.

Portfolio Pulse from Benzinga Newsdesk

November 30, 2023 | 4:31 pm

AZEK

BMO Capital analyst Ketan Mamtora has maintained an Outperform rating on AZEK Co (NYSE:AZEK) and increased the price target from $37 to $39.

Portfolio Pulse from Benzinga Newsdesk

November 30, 2023 | 4:30 pm

NTAP

Citigroup analyst Jim Suva has maintained a Neutral rating on NetApp (NASDAQ:NTAP) and increased the company's price target from $83 to $90.

Portfolio Pulse from Benzinga Newsdesk

November 30, 2023 | 4:22 pm

IMGN

HC Wainwright & Co. analyst Swayampakula Ramakanth downgraded Immunogen (NASDAQ:IMGN) from Buy to Neutral, while increasing the price target from $28 to $31.26.

Portfolio Pulse from Benzinga Newsdesk

November 30, 2023 | 4:13 pm

NEXCF

HC Wainwright & Co. analyst Scott Buck has maintained a Buy rating on Nextech3d AI (OTC:NEXCF) but has reduced the price target from $1 to $0.5.

Portfolio Pulse from Benzinga Newsdesk

November 30, 2023 | 4:11 pm

TYGO

Roth MKM analyst Philip Shen has maintained a Neutral rating on Tigo Energy (NASDAQ:TYGO) and lowered the price target from $2.5 to $2.2, as reported on November 29, 2023.

Portfolio Pulse from Benzinga Newsdesk

November 30, 2023 | 4:03 pm

CI

Cigna Group (NYSE:CI) has received 5 indifferent analyst ratings in the last quarter with no bullish or bearish ratings. The average price target is $325.0, representing an implied upside from the current price of $262.11. This target has increased by 8.09% from the previous target of $300.67. Analyst ratings are based on future earnings predictions and company performance analysis.

Portfolio Pulse from Benzinga Insights

November 30, 2023 | 4:00 pm